The FDA decision comes just over two months after Biogen Idec Inc (NASDAQ:BIIB) won backing for another haemophilia drug with the US approval of Alprolix to treat haemophilia B.Both drugs were developed in partnership with Swedish Orphan Biovitrum (Sobi), a biopharma that specialises in rare diseases. The A and B variants of haemophilia are classed as rare diseases in the US allowing Eloctate and Alprolix to be assessed as orphan products, giving certain incentives to Biogen Idec. Biogen Idec Inc (NASDAQ:BIIB) net profit margin is 25.00% and weekly performance is -2.38%. On last trading day company shares ended up $309.98. Analysts mean target price for the company is $348.70. Biogen Idec Inc (NASDAQ:BIIB) distance from 50-day simple moving average is 4.07%.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA)‘s stock had its “neutral” rating reiterated by research analysts at JPMorgan Chase & Co. in a report released on Tuesday. They currently have a $56.00 price target on the stock, up from their previous price target of $55.00. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares advanced 0.31% in last trading session and ended the day on $51.98. TEVA Gross Margin is 53.00% and its return on assets is 2.90%. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) quarterly performance is 7.09%.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced that on June 11, 2014, two scientific posters associated with its study of NBI-98854 in Phase IIb clinical trials of tardive dyskinesia patients, will be presented at the 2014 Annual Congress of Parkinson’s Disease and Movement Disorders in Stockholm Sweden. This annual meeting brings together over 5,000 clinicians and scientists from around the world to address current topics related to movement disorders. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares moved down -1.45% in last trading session and was closed at $14.97, while trading in range of $14.70-$15.34. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) year to date performance is 60.28%.
GlaxoSmithKline plc (NYSE:GSK)‘s stock had its “hold” rating restated by research analysts at Deutsche Bank in a report released on Tuesday. GlaxoSmithKline plc (ADR) (NYSE:GSK) ended the last trading day at $54.50. Company weekly volatility is calculated as 0.61% and price to cash ratio as 21.92. GlaxoSmithKline plc (ADR) (NYSE:GSK) showed a positive weekly performance of 1.49%.
Drug firm Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY) launched Melgain lotion used for treatment of vitiligo, a skin disorder in India under a partnership with Issar Pharmaceuticals Pvt Ltd. Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY) net profit margin is 24.40% and weekly performance is 1.94%. On last trading day company shares ended up $40.42. Analysts mean target price for the company is $48.75. Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY) distance from 50-day simple moving average is -4.37%.